AI Engines For more Details: Perplexity Kagi Labs You
Angina Pectoris: Nicorandil is primarily used for the prevention and treatment of angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. It works by dilating the blood vessels (both arteries and veins), which increases blood flow to the heart and reduces the workload on the heart muscle. This helps relieve angina symptoms and may reduce the frequency and severity of angina attacks.
Coronary Artery Disease (CAD): Nicorandil is beneficial in patients with coronary artery disease, where there is a buildup of plaque in the arteries that supply blood to the heart. By dilating coronary arteries, nicorandil improves blood flow to the heart muscle, which can help prevent ischemia (lack of oxygen) and reduce the risk of myocardial infarction (heart attack).
Hypertension: Nicorandil's vasodilatory effects also extend to systemic arteries, leading to a reduction in peripheral vascular resistance and blood pressure. While not typically used as a first-line treatment for hypertension, nicorandil may be considered in individuals with concomitant angina and hypertension or in those who have not responded adequately to other antihypertensive medications.
Coronary Artery Spasm: Nicorandil is particularly effective in preventing and relieving coronary artery spasm (vasospasm), which can lead to angina or myocardial infarction. Its dual mechanism of action as both a potassium channel opener and a nitric oxide donor helps relax smooth muscle cells in the blood vessel walls, preventing spasm and promoting vasodilation.
Heart Failure: Some studies have suggested potential benefits of nicorandil in patients with heart failure, particularly those with preserved ejection fraction (HFpEF). Nicorandil's vasodilatory and anti-ischemic properties may help improve cardiac function, reduce symptoms, and enhance exercise tolerance in these patients. However, more research is needed to establish its role in heart failure management.
Peripheral Arterial Disease (PAD): Nicorandil's vasodilatory effects may also benefit individuals with peripheral arterial disease by improving blood flow to the limbs, relieving symptoms such as intermittent claudication (leg pain during walking), and promoting wound healing. However, its use in this context is less common compared to other medications like cilostazol.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Anaerobutyricum hallii | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Christensenella minuta | Reduces |
| species | Lactococcus cremoris | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 0 | 1 | Bacteroides luhongzhouii | species | Decreases |
| 0 | 1 | Bacteroides sp. DH3716P | species | Decreases |
| 0 | 1 | Enterocloster clostridioformis | species | Decreases |
| 0 | 1 | Bacteroides sp. D2 | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Flavonifractor plautii | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Hungatella hathewayi | species | Decreases |
| 0 | 1 | Blautia obeum | species | Decreases |
| 0 | 1 | Bacteroides sp. M10 | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Eubacterium ventriosum | species | Decreases |
| 0 | 1 | Butyrivibrio crossotus | species | Decreases |
| 0 | 1 | Wansuia hejianensis | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 0 | 1 | Fannyhessea vaginae | species | Decreases |
| 0 | 1 | Bacteroides faecium | species | Decreases |
| 0 | 1 | Ligilactobacillus ruminis | species | Decreases |
| 0 | 1 | Komagataeibacter oboediens | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Subdoligranulum variabile | species | Decreases |
| 0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
| 0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
| 0 | 1 | Roseburia rectibacter | species | Decreases |
| 0 | 1 | Olsenella sp. oral taxon 807 | species | Decreases |
| 0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
| 0 | 1 | Faecalibacillus intestinalis | species | Decreases |
| 0 | 1 | Adlercreutzia equolifaciens | species | Decreases |
| 0 | 1 | Bacillus paralicheniformis | species | Decreases |
| 0 | 1 | Clostridium sp. SY8519 | species | Decreases |
| 0 | 1 | Actinomyces naeslundii | species | Decreases |
| 0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
| 0 | 1 | Bacteroides caecimuris | species | Decreases |
| 0 | 1 | [Ruminococcus] lactaris | species | Decreases |
| 0 | 1 | Clostridium sp. M62/1 | species | Decreases |
| 0 | 1 | Blautia liquoris | species | Decreases |
| 0 | 1 | Faecalibacterium duncaniae | species | Decreases |
| 0 | 1 | Blautia parvula | species | Decreases |
| 0 | 1 | Streptococcus mutans | species | Decreases |
| 0 | 1 | Intestinibaculum porci | species | Decreases |
| 0 | 1 | Coprococcus eutactus | species | Decreases |
| 0 | 1 | Mogibacterium diversum | species | Decreases |
| 0 | 1 | Anaerostipes hadrus | species | Decreases |
| 0 | 1 | Lactococcus cremoris | species | Decreases |
| 0 | 1 | Wujia chipingensis | species | Decreases |
| 0 | 1 | Actinomyces sp. oral taxon 169 | species | Decreases |
| 0 | 1 | Christensenella minuta | species | Decreases |
| 0 | 1 | Actinomyces oris | species | Decreases |
| 0 | 1 | Streptococcus suis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| ADHD | 2.3 | 0.4 | 4.75 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.1 | 4 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.4 | 2 |
| Allergies | 2.4 | 1.8 | 0.33 |
| Allergy to milk products | 1 | 0.6 | 0.67 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 3.8 | 3 | 0.27 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.5 | 2.2 |
| Ankylosing spondylitis | 1.3 | 1.7 | -0.31 |
| Anorexia Nervosa | 0.8 | 1.9 | -1.37 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
| Asthma | 2.4 | 0.5 | 3.8 |
| Atherosclerosis | 1.6 | 0.4 | 3 |
| Atrial fibrillation | 2.4 | 0.8 | 2 |
| Autism | 4.6 | 4.6 | 0 |
| Autoimmune Disease | 0.1 | 0.1 | 0 |
| Barrett esophagus cancer | 0.4 | 0.1 | 3 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1 | 0.7 | 0.43 |
| Brain Trauma | 0.1 | 0.9 | -8 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.5 | 0.1 | 4 |
| Carcinoma | 2.6 | 1.4 | 0.86 |
| Celiac Disease | 1.7 | 1.7 | 0 |
| Cerebral Palsy | 0.5 | 0.9 | -0.8 |
| Chronic Fatigue Syndrome | 3.7 | 4.9 | -0.32 |
| Chronic Kidney Disease | 1.4 | 1.4 | 0 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.1 | 0.18 |
| Chronic Urticaria (Hives) | 0.2 | 0.3 | -0.5 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.7 | -1.33 |
| Cognitive Function | 1.5 | 0.3 | 4 |
| Colorectal Cancer | 4.4 | 1.1 | 3 |
| Constipation | 1.8 | 0 | 0 |
| Coronary artery disease | 1.2 | 1.5 | -0.25 |
| COVID-19 | 5.2 | 8 | -0.54 |
| Crohn's Disease | 4.3 | 3.8 | 0.13 |
| Cushing's Syndrome (hypercortisolism) | 1 | -1 | |
| cystic fibrosis | 0.4 | -0.4 | |
| deep vein thrombosis | 1.1 | 1 | 0.1 |
| Denture Wearers Oral Shifts | 1.3 | 1.3 | |
| Depression | 4.7 | 3.7 | 0.27 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.8 | 0.9 | -0.13 |
| Endometriosis | 1.1 | 1.2 | -0.09 |
| Eosinophilic Esophagitis | 0.4 | 0.1 | 3 |
| Epilepsy | 1.3 | 0.9 | 0.44 |
| erectile dysfunction | 0.7 | 0.7 | |
| Fibromyalgia | 1.4 | 1 | 0.4 |
| Functional constipation / chronic idiopathic constipation | 3.4 | 1.8 | 0.89 |
| gallstone disease (gsd) | 1.5 | 0.4 | 2.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.8 | 1.5 |
| Generalized anxiety disorder | 1.3 | 0.7 | 0.86 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 1.6 | 0.2 | 7 |
| Graves' disease | 1 | 1.4 | -0.4 |
| Gulf War Syndrome | 0.4 | 0.9 | -1.25 |
| Halitosis | 1.5 | 0.1 | 14 |
| Hashimoto's thyroiditis | 2.3 | 0.9 | 1.56 |
| Heart Failure | 2.7 | 1.1 | 1.45 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.1 | 0.5 | -4 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.4 | 0.5 | -0.25 |
| hypertension (High Blood Pressure | 2.5 | 2.8 | -0.12 |
| Hypothyroidism | 0.2 | -0.2 | |
| Hypoxia | 0.9 | 0.9 | |
| IgA nephropathy (IgAN) | 1.6 | 2.6 | -0.63 |
| Inflammatory Bowel Disease | 4 | 4.3 | -0.07 |
| Insomnia | 1.6 | 1.6 | 0 |
| Intelligence | 0.8 | 0.8 | |
| Intracranial aneurysms | 1.3 | 0.3 | 3.33 |
| Irritable Bowel Syndrome | 3.2 | 3.2 | 0 |
| ischemic stroke | 1.1 | 0.6 | 0.83 |
| Liver Cirrhosis | 3.1 | 2 | 0.55 |
| Long COVID | 4.7 | 4.8 | -0.02 |
| Low bone mineral density | 0.7 | -0.7 | |
| Lung Cancer | 1 | -1 | |
| Mast Cell Issues / mastitis | 0.7 | 0.7 | 0 |
| ME/CFS with IBS | 0.7 | 1.9 | -1.71 |
| ME/CFS without IBS | 0.5 | 1.5 | -2 |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.9 | 0 | 0 |
| Metabolic Syndrome | 2.9 | 3.6 | -0.24 |
| Mood Disorders | 3.9 | 3.1 | 0.26 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 3 | 3.5 | -0.17 |
| Multiple system atrophy (MSA) | 0.1 | 0.5 | -4 |
| myasthenia gravis | 0.1 | 0.1 | 0 |
| neuropathic pain | 1 | -1 | |
| Neuropathy (all types) | 0.1 | 0.4 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.9 | 2 | 0.45 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 4.1 | 4.4 | -0.07 |
| obsessive-compulsive disorder | 3.7 | 1.8 | 1.06 |
| Osteoarthritis | 1.2 | 1.1 | 0.09 |
| Osteoporosis | 0.9 | 0.8 | 0.13 |
| pancreatic cancer | 0.9 | 0.1 | 8 |
| Parkinson's Disease | 3.2 | 3.8 | -0.19 |
| Polycystic ovary syndrome | 4.2 | 1.8 | 1.33 |
| Postural orthostatic tachycardia syndrome | 0 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| primary biliary cholangitis | 0.5 | 0.8 | -0.6 |
| Primary sclerosing cholangitis | 1.2 | 1.5 | -0.25 |
| Psoriasis | 1.6 | 1.1 | 0.45 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 2.1 | 0.95 |
| Rosacea | 0.9 | 0.1 | 8 |
| Schizophrenia | 2.6 | 1.5 | 0.73 |
| scoliosis | 0.3 | 1.1 | -2.67 |
| sensorineural hearing loss | 0.2 | 0.2 | |
| Sjögren syndrome | 0.4 | 1.2 | -2 |
| Sleep Apnea | 1.4 | 0.6 | 1.33 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 1.3 | 0.7 | 0.86 |
| Systemic Lupus Erythematosus | 1.8 | 1.3 | 0.38 |
| Tic Disorder | 1.4 | 0.5 | 1.8 |
| Tourette syndrome | 0.5 | 0.3 | 0.67 |
| Type 1 Diabetes | 2.8 | 2.2 | 0.27 |
| Type 2 Diabetes | 4.7 | 3.9 | 0.21 |
| Ulcerative colitis | 2.9 | 4 | -0.38 |
| Unhealthy Ageing | 4.1 | 0.8 | 4.12 |
| Vitiligo | 1.7 | 0.5 | 2.4 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
